| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 554 | 2019 |
| Plasma ghrelin following cure of Helicobacter pylori CU Nwokolo, DA Freshwater, P O’hare, HS Randeva Gut 52 (5), 637-640, 2003 | 336 | 2003 |
| HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease A Sazonovs, NA Kennedy, L Moutsianas, GA Heap, DL Rice, M Reppell, ... Gastroenterology 158 (1), 189-199, 2020 | 303 | 2020 |
| Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. JT Smith, RE Pounder, CU Nwokolo, S Lanzon-Miller, DG Evans, ... Gut 31 (5), 522-525, 1990 | 240 | 1990 |
| Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus Esophageal Adenocarcinoma Genetics Consortium, ... Nature genetics 44 (10), 1131-1136, 2012 | 206 | 2012 |
| Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis RP Arasaradnam, MJ McFarlane, C Ryan-Fisher, E Westenbrink, ... PloS one 9 (9), e108750, 2014 | 169 | 2014 |
| Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. CU Nwokolo, JT Smith, C Gavey, A Sawyerr, RE Pounder Alimentary Pharmacology & Therapeutics 4, 29-45, 1990 | 160 | 1990 |
| Development and application of a new electronic nose instrument for the detection of colorectal cancer E Westenbrink, RP Arasaradnam, N O'Connell, C Bailey, C Nwokolo, ... Biosensors and Bioelectronics 67, 733-738, 2015 | 143 | 2015 |
| Next generation diagnostic modalities in gastroenterology–gas phase volatile compound biomarker detection RP Arasaradnam, JA Covington, C Harmston, CU Nwokolo Alimentary pharmacology & therapeutics 39 (8), 780-789, 2014 | 142 | 2014 |
| A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis PM Irving, T Iqbal, C Nwokolo, S Subramanian, S Bloom, N Prasad, A Hart, ... Inflammatory bowel diseases 24 (4), 714-724, 2018 | 141 | 2018 |
| Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients MM Widlak, CL Thomas, MG Thomas, C Tomkins, S Smith, N O'Connell, ... Alimentary pharmacology & therapeutics 45 (2), 354-363, 2017 | 121 | 2017 |
| Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus C Palles, L Chegwidden, X Li, JM Findlay, G Farnham, FC Giner, ... Gastroenterology 148 (2), 367-378, 2015 | 116 | 2015 |
| Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? A Dhaliwal, Z Zeino, C Tomkins, M Cheung, C Nwokolo, S Smith, ... Frontline Gastroenterology 6 (1), 14-19, 2015 | 113 | 2015 |
| Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial C Mowat, I Arnott, A Cahill, M Smith, T Ahmad, S Subramanian, S Travis, ... The lancet Gastroenterology & hepatology 1 (4), 273-282, 2016 | 110 | 2016 |
| Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non‐alcoholic steatohepatitis A Sajjad, M Mottershead, WK Syn, R Jones, S Smith, CU Nwokolo Alimentary pharmacology & therapeutics 22 (4), 291-299, 2005 | 102 | 2005 |
| Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. CU Nwokolo, JT Smith, AM Sawyerr, RE Pounder Gut 32 (12), 1455-1460, 1991 | 89 | 1991 |
| A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease RP Arasaradnam, N Ouaret, MG Thomas, N Quraishi, E Heatherington, ... Inflammatory bowel diseases 19 (5), 999-1003, 2013 | 87 | 2013 |
| Eradication of Helicobacter pylori abolishes 24‐hour hypergastrinaemia: a prospective study in healthy subjects EJ Prewett, JTL Smith, CU Nwokolo, M Hudson, AM Sawyerr, RE Pounder Alimentary pharmacology & therapeutics 5 (3), 283-290, 1991 | 87 | 1991 |
| Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis–a pilot study RP Arasaradnam, E Westenbrink, MJ McFarlane, R Harbord, S Chambers, ... PloS one 9 (10), e107312, 2014 | 86 | 2014 |
| Application of a novel tool for diagnosing bile acid diarrhoea JA Covington, EW Westenbrink, N Ouaret, R Harbord, C Bailey, ... Sensors 13 (9), 11899-11912, 2013 | 82 | 2013 |
